Aeroneb drug delivery items receive marketing authorisation in China Aerogen.

Chinese annual spending on healthcare has an attractive 20 percent growth rate, representing a significant opportunity for advanced technologies to flourish. Aerogen can be no stranger to high growth, having increased sales 30 percent calendar year on year since its administration buyout in 2008, an achievement recently recognised with the award of the Ruban d’Honneur because of its international growth strategy at the European Business Awards. ‘Aerogen is assured of a strong entry into the Chinese market. We expect to see Aerogen items in use in China by the finish of March 2012, which will be a substantial milestone in our planned move into emergent, high-growth regional marketplaces.’ John Power said.. Continue reading